NewAmsterdam Pharma Co. and partner Menarini Group announced that the European Commission granted marketing authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) across EU Member States, Iceland, Liechtenstein, and Norway. This marks the first global regulatory approval for obicetrapib. The Company is entitled to tiered double-digit percentage royalties on net sales in the Menarini Territory and up to an additional €833 million in clinical, regulatory, and commercial milestones. Milestone payments in the mid-teens of millions of euros are triggered by these specific marketing authorizations. NewAmsterdam Pharma Co. operates in the biopharmaceutical industry, developing therapies for cardiovascular disease.
